(Circulation. 1995;91:2043-2048.)
© 1995 American Heart Association, Inc.
Articles |
Bradykinin Antagonism Inhibits the Antigrowth Effect of Converting Enzyme Inhibition in the Dog Myocardium After Discrete Transmural Myocardial Necrosis
From the Cardiovascular Division, Department of Medicine and Department of Radiology, University of Minnesota, Minneapolis.
Correspondence to Kenneth M. McDonald, MD, Assistant Professor of Medicine, Cardiovascular Division, University of Minnesota Medical School, Box 508 UMHC, 420 Delaware St SE, Minneapolis, MN 55455.
Background Converting enzyme inhibitor (CEI) therapy, but not angiotensin II subtype I receptor blockade, has been shown to attenuate left ventricular remodeling in the dog after transmyocardial direct current (DC) shock. The purpose of this study was to address the importance of preservation of bradykinin to the antiremodeling effect of CEI treatment in this model.
Methods and Results Twenty-four hours after DC shock, adult mongrel dogs were assigned to one of three groups: a control group; a group treated with ramipril 10 mg BID; and a group treated with ramipril 10 mg BID along with a continuous subcutaneous infusion of HOE 140, a bradykinin antagonist. To assess change in left and right ventricular structure, a magnetic resonance imaging (MRI) study was performed 4 weeks after DC shock and compared with a baseline MRI study performed before DC shock. The increase in left ventricular mass (mean±SEM) in the control group was similar to that observed in the CEI–HOE 140 group (+0.73±0.19 versus +0.75±0.18 g/kg, P=NS), but both were greater than the change in mass in the ramipril group (-0.48±0.13 g/kg, P=.004 and P=.0005, respectively). No significant change occurred in left ventricular volume or right ventricular structure in any group. Mean arterial pressure was reduced by ramipril compared with the control group (-8±2 versus +7±2 mm Hg, P=.03), and this effect was not blunted by the addition of HOE 140 (-7±3 mm Hg).
Conclusions Prevention by ramipril of the early increase in left ventricular mass in the DC shock model appears to be related to the preservation of bradykinin.
Key Words: bradykinin • ventricles • angiotensin • enzymes • myocardium
This article has been cited by other articles:
 |
|
 |
|
  J. H. Levy, K. A. Tanaka, and J. M. Bailey Cardiac Surgical Pharmacology Card. Surg. Adult, January 1, 2008; 3(2008): 77 - 110. [Full Text]
|
|
|
|
 |
|
 M Yoshiyama, Y Nakamura, T Omura, Y Izumi, R Matsumoto, S Oda, K Takeuchi, S Kim, H Iwao, and J Yoshikawa Angiotensin converting enzyme inhibitor prevents left ventricular remodelling after myocardial infarction in angiotensin II type 1 receptor knockout mice Heart, August 1, 2005; 91(8): 1080 - 1085. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Liesmaa, A. Kuoppala, N. Shiota, J. O. Kokkonen, K. Kostner, M. Mayranpaa, P. T. Kovanen, and K. A. Lindstedt Increased expression of bradykinin type-1 receptors in endothelium of intramyocardial coronary vessels in human failing hearts Am J Physiol Heart Circ Physiol, May 1, 2005; 288(5): H2317 - H2322. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Yang, X.-P. Yang, Y.-H. Liu, J. Xu, O. Cingolani, N.-E. Rhaleb, and O. A. Carretero Ac-SDKP Reverses Inflammation and Fibrosis in Rats With Heart Failure After Myocardial Infarction Hypertension, February 1, 2004; 43(2): 229 - 236. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kasama, T. Toyama, H. Kumakura, Y. Takayama, S. Ichikawa, T. Suzuki, and M. Kurabayashi Addition of Valsartan to an Angiotensin-Converting Enzyme Inhibitor Improves Cardiac Sympathetic Nerve Activity and Left Ventricular Function in Patients with Congestive Heart Failure J. Nucl. Med., June 1, 2003; 44(6): 884 - 890. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.N Cohn Angiotensin receptor blockers and clinical trials in heart failure Eur. Heart J., January 2, 2003; 24(2): 125 - 126. [Full Text] [PDF]
|
|
|
|
 |
|
 D. L. Brutsaert Cardiac Endothelial-Myocardial Signaling: Its Role in Cardiac Growth, Contractile Performance, and Rhythmicity Physiol Rev, January 1, 2003; 83(1): 59 - 115. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Bailey, K. A. Tanaka, and J. H. Levy Cardiac Surgical Pharmacology Card. Surg. Adult, January 1, 2003; 2(2003): 85 - 118. [Full Text]
|
|
|
|
 |
|
 Y. Nakamura, M. Yoshiyama, T. Omura, K. Yoshida, Y. Izumi, K. Takeuchi, S. Kim, H. Iwao, and J. Yoshikawa Beneficial effects of combination of ACE inhibitor and angiotensin II type 1 receptor blocker on cardiac remodeling in rat myocardial infarction Cardiovasc Res, January 1, 2003; 57(1): 48 - 54. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Agata, L. Chao, and J. Chao Kallikrein Gene Delivery Improves Cardiac Reserve and Attenuates Remodeling After Myocardial Infarction Hypertension, November 1, 2002; 40(5): 653 - 659. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Kuoppala, N. Shiota, J. O. Kokkonen, I. Liesmaa, K. Kostner, M. Mayranpaa, P. T. Kovanen, and K. A. Lindstedt Down-regulation of cardioprotective bradykinin type-2 receptors in the left ventricle of patients with end-stage heart failure J. Am. Coll. Cardiol., July 3, 2002; 40(1): 119 - 125. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Multani, R. S. Krombach, A. T. Goldberg, M. K. King, J. W. Hendrick, J. A. Sample, S. C. Baicu, C. Joffs, M. deGasparo, and F. G. Spinale Myocardial Bradykinin Following Acute Angiotensin-Converting Enzyme Inhibition, AT1 Receptor Blockade, or Combined Inhibition in Congestive Heart Failure Journal of Cardiovascular Pharmacology and Therapeutics, December 1, 2001; 6(4): 369 - 376. [Abstract] [PDF]
|
|
|
|
 |
|
 S. Kanno, Y.-J. L. Wu, P. C. Lee, T. R. Billiar, and C. Ho Angiotensin-Converting Enzyme Inhibitor Preserves p21 and Endothelial Nitric Oxide Synthase Expression in Monocrotaline-Induced Pulmonary Arterial Hypertension in Rats Circulation, August 21, 2001; 104(8): 945 - 950. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Mankad, T. A. d'Amato, N. Reichek, W. E. McGregor, J. Lin, D. Singh, W. J. Rogers, and C. M. Kramer Combined Angiotensin II Receptor Antagonism and Angiotensin-Converting Enzyme Inhibition Further Attenuates Postinfarction Left Ventricular Remodeling Circulation, June 12, 2001; 103(23): 2845 - 2850. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. V. Exner, D. L. Dries, M. J. Domanski, and J. N. Cohn Lesser Response to Angiotensin-Converting-Enzyme Inhibitor Therapy in Black as Compared with White Patients with Left Ventricular Dysfunction N. Engl. J. Med., May 3, 2001; 344(18): 1351 - 1357. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. G. Myerson, H. E. Montgomery, M. Whittingham, M. Jubb, M. J. World, S. E. Humphries, and D. J. Pennell Left Ventricular Hypertrophy With Exercise and ACE Gene Insertion/Deletion Polymorphism : A Randomized Controlled Trial With Losartan Circulation, January 16, 2001; 103(2): 226 - 230. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Tamura, S. Said, J. Harris, W. Lu, and A. M. Gerdes Reverse Remodeling of Cardiac Myocyte Hypertrophy in Hypertension and Failure by Targeting of the Renin-Angiotensin System Circulation, July 11, 2000; 102(2): 253 - 259. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Kuoppala, K. A. Lindstedt, J. Saarinen, P. T. Kovanen, and J. O. Kokkonen Inactivation of bradykinin by angiotensin-converting enzyme and by carboxypeptidase N in human plasma Am J Physiol Heart Circ Physiol, April 1, 2000; 278(4): H1069 - H1074. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Baudet Hypertrophy and dilation: a TOTally new story? Cardiovasc Res, April 1, 2000; 46(1): 17 - 19. [Full Text] [PDF]
|
|
|
|
|
|
S. B. Parker, A. D. Dobrian, S. S. Wade, and R. L. Prewitt AT1 receptor inhibition does not reduce arterial wall hypertrophy or PDGF-A expression in renal hypertension Am J Physiol Heart Circ Physiol, February 1, 2000; 278(2): H613 - H622. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. J. Dell’Italia and S. Oparil Bradykinin in the Heart : Friend Or Foe? Circulation, December 7, 1999; 100(23): 2305 - 2307. [Full Text] [PDF]
|
|
|
|
|
|
K. Harada, T. Sugaya, K. Murakami, Y. Yazaki, and I. Komuro Angiotensin II Type 1A Receptor Knockout Mice Display Less Left Ventricular Remodeling and Improved Survival After Myocardial Infarction Circulation, November 16, 1999; 100(20): 2093 - 2099. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. McKelvie, S. Yusuf, D. Pericak, A. Avezum, R. J. Burns, J. Probstfield, R. T. Tsuyuki, M. White, J. Rouleau, R. Latini, et al. Comparison of Candesartan, Enalapril, and Their Combination in Congestive Heart Failure : Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study: The RESOLVD Pilot Study Investigators Circulation, September 7, 1999; 100(10): 1056 - 1064. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. R. Bastien, A.-V. Juneau, J. Ouellette, and C. Lambert Chronic AT1 receptor blockade and angiotensin-converting enzyme (ACE) inhibition in (CHF 146) cardiomyopathic hamsters: effects on cardiac hypertrophy and survival Cardiovasc Res, July 1, 1999; 43(1): 77 - 85. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Baruch, I. Anand, I. S. Cohen, S. Ziesche, D. Judd, and J. N. Cohn Augmented Short- and Long-Term Hemodynamic and Hormonal Effects of an Angiotensin Receptor Blocker Added to Angiotensin Converting Enzyme Inhibitor Therapy in Patients With Heart Failure Circulation, May 25, 1999; 99(20): 2658 - 2664. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. O. Kokkonen, A. Kuoppala, J. Saarinen, K. A. Lindstedt, and P. T. Kovanen Kallidin- and Bradykinin-Degrading Pathways in Human Heart : Degradation of Kallidin by Aminopeptidase M–Like Activity and Bradykinin by Neutral Endopeptidase Circulation, April 20, 1999; 99(15): 1984 - 1990. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A.-M. Duncan, G. M. James, F. Anastasopoulos, A. Kladis, T. A. Briscoe, and D. J. Campbell Interaction Between Neutral Endopeptidase and Angiotensin Converting Enzyme Inhibition in Rats with Myocardial Infarction: Effects on Cardiac Hypertrophy and Angiotensin and Bradykinin Peptide Levels J. Pharmacol. Exp. Ther., April 1, 1999; 289(1): 295 - 303. [Abstract] [Full Text]
|
|
|
|
|
|
M. Tanimura, V. G. Sharov, H. Shimoyama, T. Mishima, T. B. Levine, S. Goldstein, and H. N. Sabbah Effects of AT1-receptor blockade on progression of left ventricular dysfunction in dogs with heart failure Am J Physiol Heart Circ Physiol, April 1, 1999; 276(4): H1385 - H1392. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Yoshiyama, K. Takeuchi, T. Omura, S. Kim, H. Yamagishi, I. Toda, M. Teragaki, K. Akioka, H. Iwao, and J. Yoshikawa Effects of Candesartan and Cilazapril on Rats With Myocardial Infarction Assessed by Echocardiography Hypertension, April 1, 1999; 33(4): 961 - 968. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Koide, B. A. Carabello, C. C. Conrad, J. M. Buckley, G. DeFreyte, M. Barnes, R. J. Tomanek, C.-C. Wei, L. J. Dell'Italia, G. Cooper IV, et al. Hypertrophic response to hemodynamic overload: role of load vs. renin-angiotensin system activation Am J Physiol Heart Circ Physiol, February 1, 1999; 276(2): H350 - H358. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. B. Parker, S. S. Wade, and R. L. Prewitt Pressure Mediates Angiotensin II–Induced Arterial Hypertrophy and PDGF-A Expression Hypertension, September 1, 1998; 32(3): 452 - 458. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Gallagher, H. Yu, and M. P. Printz Bradykinin-Induced Reductions in Collagen Gene Expression Involve Prostacyclin Hypertension, July 1, 1998; 32(1): 84 - 88. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R.S. Krombach, M. J Clair, J. W Hendrick, W. V Houck, J. L Zellner, S. B Kribbs, S. Whitebread, R. Mukherjee, M. de Gasparo, and F. G Spinale Angiotensin converting enzyme inhibition, AT1 receptor inhibition, and combination therapy with pacing induced heart failure: effects on left ventricular performance and regional blood flow patterns Cardiovasc Res, June 1, 1998; 38(3): 631 - 645. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Partovian, A. Benetos, J.-P. Pommies, W. Mischler, and M. E. Safar Effects of a chronic high-salt diet on large artery structure: role of endogenous bradykinin Am J Physiol Heart Circ Physiol, May 1, 1998; 274(5): H1423 - H1428. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Hamawaki, T. M. Coffman, A. Lashus, M. Koide, M. R. Zile, M. I. Oliverio, G. Defreyte, G. Cooper IV, and B. A. Carabello Pressure-overload hypertrophy is unabated in mice devoid of AT1A receptors Am J Physiol Heart Circ Physiol, March 1, 1998; 274(3): H868 - H873. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. G. Spinale, H. H. Holzgrefe, R. Mukherjee, M. L. Webb, R. B. Hird, M. J. Cavallo, J. R. Powell, and W. H. Koster Angiotensin-Converting Enzyme Inhibition and Angiotensin II Subtype-1 Receptor Blockade during the Progression of Left Ventricular Dysfunction: Differential Effects on Myocyte Contractile Processes J. Pharmacol. Exp. Ther., December 1, 1997; 283(3): 1082 - 1094. [Abstract] [Full Text]
|
|
|
|
 |
|
 A. Benetos, B. I. Levy, P. Lacolley, F. Taillard, M. Duriez, and M. E. Safar Role of Angiotensin II and Bradykinin on Aortic Collagen Following Converting Enzyme Inhibition in Spontaneously Hypertensive Rats Arterioscler. Thromb. Vasc. Biol., November 1, 1997; 17(11): 3196 - 3201. [Abstract] [Full Text]
|
|
|
|
|
|
F. G. Spinale, M. de Gasparo, S. Whitebread, L. Hebbar, M. J. Clair, D. M. Melton, R. S. Krombach, R. Mukherjee, J. P. Iannini, and S.-J. O Modulation of the Renin-Angiotensin Pathway Through Enzyme Inhibition and Specific Receptor Blockade in Pacing-Induced Heart Failure : I. Effects on Left Ventricular Performance and Neurohormonal Systems Circulation, October 7, 1997; 96(7): 2385 - 2396. [Abstract] [Full Text]
|
|
|
|
|
|
K. C. Wollert, R. Studer, K. Doerfer, E. Schieffer, C. Holubarsch, H. Just, and H. Drexler Differential Effects of Kinins on Cardiomyocyte Hypertrophy and Interstitial Collagen Matrix in the Surviving Myocardium After Myocardial Infarction in the Rat Circulation, April 1, 1997; 95(7): 1910 - 1917. [Abstract] [Full Text]
|
|
|
|
|
|
J. N. Cohn Structural Basis for Heart Failure : Ventricular Remodeling and Its Pharmacological Inhibition Circulation, May 15, 1995; 91(10): 2504 - 2507. [Full Text]
|
|